Updates are available Correction dated 2022-06-07
Click to view Correction: https://doi.org/10.1007/s12015-022-10396-y
-
Authors
Lee, Jea-Young
Tuazon, Julian P.
Corey, Sydney
Bonsack, Brooke
Acosta, Sandra
Ehrhart, Jared
Sanberg, Paul R.
Borlongan, Cesario V. http://orcid.org/0000-0002-2966-9782
-
Funding
Funding for this research was provided by:
Saneron CCEL Therapeutics
- License Information
-
More Information
Article History
First Online: 17 July 2019
Change Date: 7 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12015-022-10396-y
Compliance with Ethical Standards
:
: P.R.S. is a co-founder for Saneron CCEL Therapeutics, Inc. J.E. is the Director of Research and Development for Saneron CCEL Therapeutics, Inc. P.R.S. and C.V.B. have patents for the application of hUCB as a cell therapy for several disorders. J.Y.L., J.P.T., S.C., B.B., and S.A., have no conflicts of interest to disclose.
: All procedures performed in studies involving human tissue were in accordance with the ethical standards of the Institutional Research Board at the University of South Florida (USF) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Saneron CCEL Therapeutics obtain approval under USF IRB# 131111. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the University of South Florida Institutional Animal Care and Use Committee under permit number: IS00003373.
